SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - SpringWorks Therapeutics reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.72, representing an earnings surprise of -44.44% [1] - The company posted revenues of $61.55 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.52%, and showing significant growth from $5.45 million in the same quarter last year [2] - Over the last four quarters, SpringWorks has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - SpringWorks Therapeutics shares have increased approximately 54.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.73 on revenues of $64.18 million, and for the current fiscal year, it is -$2.05 on revenues of $332.27 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which SpringWorks belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]